FMC-R regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}R-FMC regimen;FCM-R regimen ==Overview== {{PAGENAME}} refers to a regimen consisting of fludarabine, mitoxantrone, cy..." |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} {{CMG}}; {{AE}} {{AV}} | ||
{{CMG}}; {{AE}} {{AV}} | |||
{{SK}}R- | {{SK}} FCMR regimen; FCM-R regimen; FMC-R regimen; R-FCM regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone regimen | ||
==Overview== | ==Overview== | ||
| Line 18: | Line 17: | ||
==Indications== | ==Indications== | ||
*[[ | *Indolent [[non-Hodgkin's lymphoma]] and relapsed or refractory [[mantle cell lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63463&ns=NCI_Thesaurus}}</ref> | ||
*[[CLL]]<ref name="pmid19646755">{{cite journal| author=Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ| title=Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. | journal=Leuk Res | year= 2010 | volume= 34 | issue= 3 | pages= 284-8 | pmid=19646755 | doi=10.1016/j.leukres.2009.07.008 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19646755 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Latest revision as of 18:17, 31 March 2015
|
WikiDoc Resources for FMC-R regimen |
|
Articles |
|---|
|
Most recent articles on FMC-R regimen Most cited articles on FMC-R regimen |
|
Media |
|
Powerpoint slides on FMC-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FMC-R regimen at Clinical Trials.gov Trial results on FMC-R regimen Clinical Trials on FMC-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FMC-R regimen NICE Guidance on FMC-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FMC-R regimen Discussion groups on FMC-R regimen Patient Handouts on FMC-R regimen Directions to Hospitals Treating FMC-R regimen Risk calculators and risk factors for FMC-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FMC-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: FCMR regimen; FCM-R regimen; FMC-R regimen; R-FCM regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone regimen
Overview
FMC-R regimen refers to a regimen consisting of fludarabine, mitoxantrone, cyclophosphamide and rituximab, used in the treatment of resistant or relapsed chronic lymphocytic leukaemia.[1]
Regimen
FFludarabine
MMitoxantrone
CCyclophosphamide
RRituximab
Indications
- Indolent non-Hodgkin's lymphoma and relapsed or refractory mantle cell lymphoma.[2]
- CLL[3]
References
- ↑ Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B; et al. (2004). "The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group". Blood. 104 (10): 3064–71. doi:10.1182/blood-2004-04-1323. PMID 15284112.
- ↑ "NCI Thesaurus".
- ↑ Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). "Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years". Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.